Please login to the form below

Not currently logged in
Email:
Password:

Taflinar

This page shows the latest Taflinar news and features for those working in and with pharma, biotech and healthcare.

BMS gets two new cancer approvals in Europe

BMS gets two new cancer approvals in Europe

all patents regardless of their BRAF status, potentially making it more useful than BRAF inhibitors such as Roche's Zelboraf (vemurafenib) and Novartis' Taflinar (dabrafenib).

Latest news

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics